<DOC>
	<DOCNO>NCT00235716</DOCNO>
	<brief_summary>The purpose study determine whether alpha-tocopherol , memantine ( Namenda ) , combination significantly delay clinical progression mild moderately demented patient Alzheimer 's disease compare placebo .</brief_summary>
	<brief_title>A Randomized , Clinical Trial Vitamin E Memantine Alzheimer 's Disease</brief_title>
	<detailed_description>Abstract : Alzheimer 's disease ( AD ) , neurodegenerative disorder result cognitive loss , behavioral problem , functional decline , characterize well-established well-known neuropathological change brain . Cognitive deficit behavioral symptom think due cholinergic neuronal degeneration loss associate oxidative stress inflammatory response . Current therapeutic strategy include effort 1. enhance cholinergic neuronal function , 2. promote neuroprotective effect , 3. block pathologic activity excessive glutamate moderate-affinity NMDA antagonist . A combination pharmacological therapy direct simultaneously improve neuronal function neuroprotection would presumably effective either treatment alone . To test hypothesis , study examine efficacy drug treatment combination 1. three FDA approve cholinesterase inhibitor facilitate central acetylcholine neurotransmission ( donepezil , rivastigmine , galantamine ) ; 2. alpha-tocopherol , fat soluble vitamin show slow rate progression AD , presumably neuroprotective mechanism reduces oxidative stress ; 3. memantine , moderate-affinity NMDA antagonist block excessive stimulation NMDA receptor glutamate . CSP # 546 double-blind , placebo-controlled , randomize , clinical trial ass efficacy add alpha-tocopherol , memantine , combination treatment functional decline mild-to-moderately demented patient Alzheimer 's disease ( MMSE 12-26 ) currently take acetylcholinesterase inhibitor ( AchEI ) . Eligible Veterans randomly assign either 1 . 2,000 IU/d alpha-tocopherol plus memantine placebo , 2 . 20 mg/d memantine ( Namenda ) plus alpha-tocopherol placebo , 3 . 2,000 IU/d alpha-tocopherol plus 20 mg/d memantine , 4. alpha-tocopherol placebo plus memantine placebo . The primary outcome study progression AD measure Alzheimer 's Disease Cooperative Study/Activities Daily Living ( ADCS/ADL ) inventory . The ADCS/ADL inventory establish outcome measure design assess functional capacity broad range dementia severity sensitive measuring dementia progression . Secondary outcome measure include follow five instrument : Alzheimer 's Disease Assessment Scale - Cognitive Subscale ( ADAS-cog ) ( cognition ) , MMSE ( cognition ) , The Dependence Scale ( function ) , Neuropsychiatric Inventory ( NPI ) ( behavior ) , Caregiver Activity Survey ( CAS ) ( caregiver time ) . Outcomes safety assessment obtain baseline every six month . The target sample size trial 620 patient ( 210 per treatment arm ) . This sample size provide 90 % power detect 4-point mean treatment difference ADCS/ADL inventory end average follow-up period , adjusted loss . The effect detect modest translate 17.7 % reduction annual rate decline therapy give alone , effect additive , approximate 35 % reduction combine therapy . These effect equivalent slow rate progression disease nearly 6 month monotherapy 12 month combine therapy . To achieve target sample size , Veterans recruit 3-year period estimate minimum follow-up 1 year maximum 4 year . A total 10 15 VA site establish enroll average one Veteran every 2 week . CSP # 546 design ass clinically economically important treatment effect . If study definitely determine alpha-tocopherol , memantine , combination delay progression AD , study would tremendously valuable reduce financial emotional cost disease VA U.S. whole .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>1 . Diagnoses possible probable Alzheimer 's disease ( NINCDSADRDA ) 2 . Presence caregiver ( friend relative ) assume responsibility medication compliance , accompany patient visit , rate patient 's condition 3 . Written informed consent patient ( surrogate ) caregiver 4 . An MMSE score 12 26 inclusive 5 . Administration maintenance dosage donepezil ( 510mg/d ) , rivastigmine ( 612mg/d ) rivastigmine ( Exelon ) patch ( 4.6 mg 9.5 mg ) , galantamine galantamine ER ( 1624mg/d ) minimum 4 week prior randomization 6 . Agreement take vitamin E supplement and/or memantine outside study ( daily multivitamin permit contain 100 IU alphatocopherol ) 1 . A nonAlzheimer primary dementia ( e.g. , vascular dementia , Lewy body dementia , frontotemporal dementia , vitamin B12 deficiency , hypothyroidism ) 2 . Current major depression , delirium , alcohol psychoactive substance abuse dependency , schizophrenia , delusional disorder define DSMIV 3 . Presence uncontrolled systemic illness would interfere participation study life expectancy le one year 4 . Pregnant intention become pregnant 5 . Enrollment another interventional clinical trial 6 . Current prescription one AChE inhibitor 7 . Current prescription warfarin 8 . Use vitamin E supplement past 2 week 9 . Use memantine past 4 week know intolerance 10 . Estimated creatinine clearance less 5ml/min ( CockcroftGault formula ) 11 . Use amantadine past 2 week</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>clinical trial</keyword>
	<keyword>randomize control trial</keyword>
	<keyword>alpha-tocopherol</keyword>
	<keyword>vitamin E</keyword>
	<keyword>Namenda</keyword>
	<keyword>memantine</keyword>
</DOC>